key: cord-0889177-1asen7gr
authors: Hoertel, Nicolas; Sánchez‐Rico, Marina; Gulbins, Erich; Kornhuber, Johannes; Carpinteiro, Alexander; Lenze, Eric J.; Reiersen, Angela M.; Abellán, Miriam; De La Muela, Pedro; Vernet, Raphaël; Blanco, Carlos; Cougoule, Céline; Beeker, Nathanaël; Neuraz, Antoine; Gorwood, Philip; Alvarado, Jesús M.; Meneton, Pierre; Limosin, Frédéric
title: Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: an observational multicenter study
date: 2021-05-29
journal: Clin Pharmacol Ther
DOI: 10.1002/cpt.2317
sha: 106e2b2a69e06c44d6c45a076f8ff241e61b5661
doc_id: 889177
cord_uid: 1asen7gr

Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the (ASM)/ceramide system may be central to SARS‐CoV‐2 infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe COVID‐19 in an observational multicenter study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID‐19, 277 (9.7%) were taking a FIASMA medication at the time of their hospital admission. The primary endpoint was a composite of intubation and/or death. We compared this endpoint between patients taking vs. not taking a FIASMA medication in time‐to‐event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow‐up of 9.2 days (SD=12.5), the primary endpoint occurred in 104 patients (37.5%) receiving a FIASMA medication, and 1,060 patients (41.4%) who did not. Despite being significantly and substantially associated with older age and greater medical severity, FIASMA medication use was significantly associated with reduced likelihood of intubation or death in both crude (HR=0.71; 95%CI=0.58‐0.87; p<0.001) and primary IPW (HR=0.58; 95%CI=0.46‐0.72; p<0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one particular FIASMA class or medication. These results show the potential importance of the ASM/ceramide system in COVID‐19 and support the continuation of FIASMA medications in these patients. Double‐blind controlled randomized clinical trials of these medications for COVID‐19 are needed.

Global spread of the novel coronavirus SARS-CoV-2 and its variants, the causative agents of coronavirus disease 2019 (COVID- 19) , has created an unprecedented infectious disease crisis worldwide. [1] [2] [3] [4] Although the availability of vaccines has raised hope for a decline of the pandemic, the search for an effective treatment for patients with COVID-19 among all available medications is still urgently needed.

Several medications commonly used for a number of medical conditions, such as depression or high blood pressure, are functional inhibitors of acid sphingomyelinase (ASM) [5] [6] [7] [8] [9] [10] or FIASMA.

FIASMA medications, as detailed in Table 1 , include for example certain antidepressants (e.g., fluoxetine, fluvoxamine, escitalopram), antihistamine medications (e.g., hydroxyzine, promethazine), antipsychotics (e.g., aripiprazole, chlorpromazine), calcium channel blockers (e.g., amlodipine, bepridil), and mucolytics (e.g., ambroxol). [5] [6] [7] [8] [9] [10] Preclinical evidence indicates that SARS-CoV-2 activates the acid sphingomyelinase (ASM)/ceramide system, resulting in the formation of ceramide-enriched membrane domains that facilitate viral entry and infection by clustering ACE2, the cellular receptor of SARS-CoV-2. 5 An in vitro study 5 showed that several FIASMA 6 5 These preclinical data were confirmed by another study that demonstrated an inhibition of the infection of cultured epithelial cells with SARS-CoV-2 by fluoxetine. 11 A scheme of the biological mechanisms proposed by Carpinteiro et al. 5, 10 underlying the potential inhibition by FIASMAs of cell infection with SARS-CoV-2 is summarized in Figure   1 .

Findings from clinical and observational studies are consistent with these preclinical data.

First, a randomized double-blind controlled study 12 

This article is protected by copyright. All rights reserved incidence of hospitalization was 0% (0 of 65) in patients with COVID-19 who opted to receive fluvoxamine and 12.5% (6 of 48) in those who declined. Second, an observational multicenter retrospective study using data from Greater Paris University Hospitals showed that use of antidepressants, mostly FIASMA antidepressants, and of the FIASMA hydroxyzine, were significantly associated with reduced mortality in patients hospitalized for COVID-19. 14,15 Third, retrospective clinical investigations among hospitalized COVID-19 patients either elderly (N=77) 16 or with hypertension as the only comorbidity 17 (N=96) showed that the use of amlodipine (a calcium channel blocker 18 and a FIASMA) may be associated with decreased mortality. Taken together, these results suggest that the ASM/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and favouring the possible repurposing of FIASMA medications against COVID-19.

To our knowledge, no clinical study to date has examined the potential usefulness of FIASMA medications as a class in patients hospitalized for severe COVID-19. Observational studies of patients with COVID-19 taking medications for other disorders can help to decide which treatment should be prioritized for randomized clinical trials and to minimize the risk for patients of being exposed to potentially ineffective or harmful treatments.

We used data from Greater Paris University Hospitals to examine the association between FIASMA medication use and the composite outcome of intubation or death among patients hospitalized for laboratory-confirmed severe COVID-19. Our primary hypothesis was that FIASMA medication use would be associated with reduced risk of intubation or death among patients hospitalized for severe COVID-19 in time-to-event analyses adjusting for sociodemographic characteristics and medical comorbidities. Additional exploratory analyses examined whether this association was specific to certain FIASMA classes (e.g., FIASMA antidepressants) or certain individual medications (e.g., fluoxetine or amlodipine).

A multicenter cohort study was conducted at 36 AP-HP hospitals from the beginning of the epidemic in France, i.e. January 24 th , until May 1 st , 2020. 14, 15, [19] [20] [21] We included all adults aged 18 years or over who have been hospitalized in these medical centers for severe COVID-19. COVID-19 was ascertained by a positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test

This article is protected by copyright. All rights reserved on nasopharyngeal or oropharyngeal swab specimens. Severe COVID-19 was defined as having at least one of the following criteria at hospital admission : respiratory rate > 24 breaths/min or < 12 breaths/min, resting peripheral capillary oxygen saturation in ambient air < 90% , temperature > 40°C, systolic blood pressure < 100 mm Hg, or high lactate levels>2mmol/L. 22 This observational study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20-20_COVID19, IRB00011591, April 8 th , 2020). AP-HP clinical Data Warehouse initiatives ensure patient information and informed consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization n°1980120 from National Commission for Information Technology and Civil Liberties (CNIL).

AP-HP Health Data Warehouse ('Entrepôt de Données de Santé (EDS)') contains all available clinical data on all inpatient visits for COVID-19 to 36 Greater Paris university hospitals. The data included patient demographic characteristics, vital signs, laboratory test and RT-PCR test results, medication administration data during the hospitalization for COVID-19, current diagnoses, discharge disposition, ventilator use data, and death certificates.

We obtained the following data for each patient at the time of the hospitalization: sex; age, which was categorized into 4 classes based on the OpenSAFELY study results 24 (i.e. 18-50, 51-70, 71-80, 81+); hospital, which was categorized into 4 classes following the administrative clustering of AP-HP hospitals in Paris and its suburbs based on their geographical location (i.e., AP-HP Centre -Paris University, Henri Mondor University Hospitals and at home hospitalization; AP-HP Nord and Hôpitaux Universitaires Paris Seine-Saint-Denis; AP-HP Paris Saclay University; and AP-HP Sorbonne University); obesity, which was defined as having a body mass index higher than 30 kg/m 2 or an International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnosis code for obesity (E66.0, E66.1, E66.2, E66.8, E66.9); selfreported current smoking status; and any medication prescribed according to compassionate use or as part of a clinical trial (e.g. hydroxychloroquine, azithromycin, remdesivir, tocilizumab, sarilumab, or dexamethasone). To take into account possible confounding by indication bias for FIASMA medications, we recorded whether patients had any current diagnosis, based on ICD-10

This article is protected by copyright. All rights reserved diagnosis codes recorded during the visit, of neoplasms and diseases of the blood (C00-D89); mental disorders (F01-F99); diseases of the nervous system (G00-G99); cardiovascular disorders (I00-I99); respiratory disorders (J00-J99); digestive disorders (K00-K95); dermatological disorders (L00-L99); diseases of the musculoskeletal system (M00-M99); diseases of the genitourinary system (N00-N99); endocrine disorders (E00-E89); and eye-ear-nose-throat disorders (H00-H95).

All medical notes and prescriptions are computerized in Greater Paris University hospitals.

Medications including their dose, frequency, date, and mode of administration were identified from medication administration data or scanned hand-written medical prescriptions, through two deep learning models based on BERT contextual embeddings 25 , one for the medications and another for their mode of administration. The model was trained on the APmed corpus, a previously annotated dataset for this task. Extracted medications names were then normalized to the Anatomical Therapeutic Chemical (ATC) terminology using approximate string matching.

FIASMA medications were defined as having a substantial in vitro functional inhibition effect on ASM (i.e., a residual ASM activity lower than 50%), as detailed elsewhere, [5] [6] [7] [8] [9] and were divided into the following classes according to their Anatomical Therapeutic Chemical (ATC) code: 26 FIASMA alimentary tract and metabolism medications (e.g., loperamide); cardiovascular system medications, subdivided into calcium channel blockers (e.g., amlodipine) and other cardiovascular medications (e.g., carvedilol); nervous system medications, subdivided according to ATC codes into psychoanaleptic (e.g., amitriptyline) and psycholeptic medications (e.g., chlorpromazine); and respiratory system medications (e.g., desloratadine).

FIASMA medication use was defined as receiving at least one FIASMA medication within the first 24 hours of hospital admission. To minimize potential confounding effects of late prescription of FIASMA medications, patients who initiated a FIASMA medication more than 24 hours after hospital admission were excluded from the analyses. Patients who received at study baseline an antipsychotic or a benzodiazepine while being hospitalized in an intensive care unit (ICU), possibly as an aid to oral intubation, were also excluded.

This article is protected by copyright. All rights reserved

Study baseline was defined as the date of hospital admission for COVID-19. The primary endpoint was the occurrence of intubation and/or death. For patients who died after intubation, the timing of the primary endpoint was defined as the time of intubation. Patients without an end-point event had their data censored on May 1 st , 2020.

We calculated frequencies of all baseline characteristics described above in patients receiving or not receiving a FIASMA medication and compared them using standardized mean differences (SMD). SMD are useful to evaluate between-group differences in baseline characteristic variables independently of their unit of measurement (i.e. for both continuous and categorical variables [27] [28] [29] ). We considered SMD greater than 0.1 as reflecting significant differences, a threshold recommended for declaring imbalance. 28 To examine the association between FIASMA medication use at baseline and the endpoint of intubation or death, we performed Cox proportional-hazards regression models. 30 To help account for the nonrandomized prescription of medications and reduce the effects of confounders, the primary analysis used propensity score analysis with inverse probability weighting (IPW). 31 The individual propensities for receiving a FIASMA medication at baseline were estimated using a multivariable logistic regression model that included sex, age, hospital, obesity, current smoking status, and medical conditions. In the inverse-probability-weighted analyses, the predicted probabilities from the propensity-score models were used to calculate the stabilized inverseprobability-weighting weights. The association between FIASMA medication use and the endpoint was then estimated using an IPW Cox regression model. In case of non-balanced covariates, an IPW multivariable Cox regression model adjusting for the non-balanced covariates was also performed. Kaplan-Meier curves were performed using the inverse-probability-weighting weights and their pointwise 95% confidence intervals were estimated using the nonparametric bootstrap method. 32 We conducted two sensitivity analyses. First, we performed a multivariable Cox regression model including as covariates the same variables used in the IPW analysis. Second, we used a univariate Cox regression model in a matched analytic sample using a 1:1 ratio, based on the same variables used for the IPW analysis and the multivariable Cox regression analysis. To reduce the

This article is protected by copyright. All rights reserved effects of confounding, optimal matching was used in order to obtain the smallest average absolute distance across all clinical characteristics between exposed patients and non-exposed matched controls.

We performed four additional exploratory analyses. First, we examined the relationships between each FIASMA class and each individual FIASMA medication with the composite endpoint of intubation or death. Second, we reproduced these analyses while comparing patients receiving any FIASMA medication at baseline to those receiving paracetamol at baseline, to mimic an active comparator, as previously done in several ongoing clinical trials. 33 This analysis sought to address a potential immortal bias, by including in the control group patients who had the same likelihood as those in the FIASMA group to survive at baseline until being prescribed a treatment. Third, because of discrepancies in the potential FIASMA in vitro effect of venlafaxine, mirtazapine, and citalopram, 5,6 we reproduced the main analyses while considering these molecules as FIASMAs, contrary to the main analyses. Finally, we reproduced the main analyses among all patients hospitalized for COVID-19, with and without clinical severity criteria at baseline.

For all associations, we performed residual analyses to assess the fit of the data, check assumptions, including proportional hazards assumption using proportional hazards tests and diagnostics based on weighted residuals, 30 and examined the potential influence of outliers. To improve the quality of result reporting, we followed the recommendations of The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Initiative. Because our main hypothesis focused on the association between FIASMA medication use at baseline and the composite endpoint of intubation or death, statistical significance was fixed a priori at two-sided p-value <0.05. Only if a significant association was found, we planned to perform additional exploratory analyses as described above. All analyses were conducted in R software version 3.6.3 (R Project for Statistical Computing).

Of the 17,131 patients hospitalized for COVID-19, ascertained with a positive COVID-19

RT-PCR test, 1,963 patients (11.5%) were excluded because of missing data or young age (i.e. less than 18 years old of age). Of these 15,168 patients, 3,224 (21.3%) met criteria for severe COVID-

This article is protected by copyright. All rights reserved 19 at hospital admission. Of these 3,224 patients, 378 (11.7%) were excluded because they started a FIASMA medication more than 24 hours after hospital admission (N=343) or because they initiated an antipsychotic or a benzodiazepine in an ICU, possibly as an aid for intubation (N=35).

Of the remaining 2,846 adult patients, 277 (9.7%) received a FIASMA medication within the first 24 hours of hospitalization, with a mean delay between hospital admission and first FIASMA medication prescription of 0.11 days (SD=0.38; interquartile range (IQR)=0.00-0.19)) (Figure 2) .

RT-PCR test results were obtained after a median delay of 0.9 days (SD=9.4; IQR=0.5-1.7) from hospital admission date. This median delay was similar (i.e., 0.9 days) in the exposed (SD=11.4; IQR=0.5-1.4) and non-exposed (SD=9.3; IQR=0.5-1.7) groups. Over a mean follow-up of 9.2 days (SD=12.5; median=6 days; IQR=2-11), 1,168 patients (41.0%) had an end-point event at the time of data cutoff on May 1 st , 2020. Among patients who received a FIASMA medication at baseline, the mean follow-up was 12.0 days (SD=12.9, median=8 days; IQR=4-14), while it was of 8.9 days (SD=12.4, median=5 days; IQR=1-11) in those who did not.

All patient characteristics, except for current smoking status, diseases of the musculoskeletal system, and Eye-Ear-Nose-Throat disorders were significantly associated with the endpoint of intubation or death. A multivariable Cox regression model showed that sex, hospital in which the patient was treated, obesity, medications according to compassionate use or as part of a clinical trial, cardiovascular disorders, respiratory disorders, neoplasms and diseases of the blood, other infectious diseases, and diseases of the genitourinary system were significantly and independently associated with the composite risk of intubation or death ( Table S1 ).

The distributions of patient characteristics according to FIASMA medication use are shown in Table 2 . In the full sample, FIASMA medication use at baseline substantially differed according to all patient characteristics, except for medications according to compassionate use or as part of a clinical trial, and the direction of the associations indicated an older age and greater medical severity of patients receiving FIASMA medication at baseline.

In the matched analytic sample and in the full sample after applying the propensity score weights, there were no substantial differences in any characteristic (Table 2; Figure S1 ).

The endpoint of intubation or death occurred in 104 patients (37.5%) who received a FIASMA medication at baseline and in 1,060 patients (41.4%) who did not. Both the crude unadjusted analysis (HR=0.71; 95%CI=0.58-0.87; p<0.01) and the primary analysis with inverse probability

This article is protected by copyright. All rights reserved weighting (IPW) (HR=0.58; 95% CI=0.46-0.72; p<0.01) showed a significant association between FIASMA medication use at baseline and reduced risk of intubation or death (Figure 3; Table 3) .

A post-hoc analysis indicated that we had 80% power in the crude analysis to detect a hazard ratio of at least 0.82 / 1.21.

In sensitivity analyses, the multivariable Cox regression model also showed a significant association (HR=0.66; 95% CI=0.53-0.83; p<0.01), as did the univariate Cox regression model in the matched analytic sample using a 1:1 ratio (HR=0.55; 95% CI=0.43-0.73; p<0.01) ( Table 3) .

Additional exploratory analyses showed that the use of FIASMA nervous system medications, and specifically FIASMA psychoanaleptic medications, was significantly associated with decreased risk of intubation or death across all analyses ( Table 4 and Table S2 ). Using FIASMA cardiovascular system medication, and specifically FIASMA calcium channel blocker medications, was also significantly associated with reduced risk of intubation or death in the primary IPW analysis, multivariable analysis, and the IPW analysis adjusted for unbalanced covariates. Hazard ratios were lower than 1 for most individual FIASMA molecules, but none of them reached statistical significance across all main and sensitivity analyses, except for hydroxyzine and escitalopram (Table S2) , possibly due to restricted statistical power. Patients receiving any FIASMA medication at baseline, and specifically a FIASMA calcium channel blocker medication, a FIASMA nervous system medication, and specifically a FIASMA psychoanaleptic medication had a significantly reduced risk of intubation or death compared with patients who received paracetamol at baseline (Table S3) . Reproducing the main analyses while considering venlafaxine, mirtazapine and citalopram as FIASMA antidepressants did not alter the significance of our results (Table S4) . Finally, including in the main analyses all patients with and without clinical severity criteria at baseline did not alter the significance of our results (Table S5) .

In this multicenter retrospective observational study involving 2,846 adult patients hospitalized for severe COVID-19, we found that FIASMA medication use at hospital admission was significantly and substantially associated with reduced risk of intubation or death, independently of sociodemographic characteristics and medical comorbidities. This association remained significant in multiple sensitivity analyses. Additional exploratory analyses suggest that this association was not explained by one specific FIASMA class or one specific FIASMA medication.

This article is protected by copyright. All rights reserved

We found that FIASMA medication use among patients hospitalized for severe COVID-19 was significantly and substantially associated with reduced risk of intubation or death, with a 42% risk reduction in the main analysis. This association was not specific to one FIASMA psychotropic class or medication. These findings are in line with prior preclinical 5, 11 and clinical [14] [15] [16] [17] evidence that FIASMA antidepressant medications may substantially prevent cells from being infected with SARS-CoV-2 in vitro, 5, 11 and that several FIASMA medications, such as fluoxetine, hydroxyzine and amlodipine at their usual respective antidepressant, antihistaminic, and antihypertensive doses, may reduce mortality among patients hospitalized for COVID-19. [14] [15] [16] [17] Several other mechanisms could be proposed to explain this association besides the involvement of the ASM/ceramide system. 34 First, antiviral effects, i.e. inhibition of viral replication, of FIASMA medications might underlie this relationship, as suggested by in vitro studies for fluoxetine, 5 chlorpromazine, 35 and amlodipine. 17 However, inhibition of viral replication was not observed with several other FIASMA medications, including paroxetine and escitalopram. 36 Second, several FIASMA medications, such as escitalopram or hydroxyzine, have high affinity for Sigma-1 receptors (S1R), 37, 38 which have been suggested to have potential value in regulating inflammation by inhibiting cytokine production in COVID-19. 39 The S1R has been shown to restrict the endonuclease activity of an Endoplasmic Reticulum (ER) stress sensor called Inositol-Requiring Enzyme1 (IRE1) and to reduce cytokine expression, without inhibiting classical inflammatory pathways. 12, 39 Because several FIASMA medications are S1R agonists in our sample, this mechanism might have overlapped their inhibition effect on ASM. However, when examining the association between the endpoint and several FIASMA medications with low or no affinity for S1R (e.g., amlodipine, paroxetine, duloxetine, and aripiprazole) 37, [40] [41] [42] [43] , the main results remained statistically significant ( Table S6 ), suggesting that inhibition of ASM could underlie this association independently of S1R.

Finally, this association may be partly mediated by the anti-inflammatory effects of FIASMA medications, which could be explained by inhibition of ASM in endothelial cells and the immune system, and might be independent of Sigma-1 receptors. First, a recent meta-analysis 44 of studies conducted in individuals with major depressive disorder following antidepressant treatment, mostly including selective serotonin reuptake inhibitors (SSRIs), supports that, overall, antidepressants may be associated with decreased plasma levels of 4 of 16 tested inflammatory mediators, including IL-10, TNF-α, CCL-2, which are associated with COVID-19 severity, 45 

This article is protected by copyright. All rights reserved well as IL-6, which is highly correlated with disease mortality. 45, 46 Second, prior in vitro and in vivo studies [47] [48] [49] suggest that some antipsychotics may have anti-inflammatory effects via glia activation, but that this activity may not be shared by all antipsychotics. However, this antiinflammatory effect was observed for both FIASMA antipsychotics (e.g. chlorpromazine) and non-FIASMA ones (e.g., haloperidol and risperidone). If the association between FIASMA psychotropic medication use and reduced risk of intubation or death is confirmed, future studies aiming at disentangling these potentially interrelated mechanisms would be needed.

Our study has several limitations. First, there are two possible major inherent biases in observational studies: unmeasured confounding and confounding by indication. However, in the case of FIASMA medications, including several antidepressants and cardiovascular system medications, confounding by indication may typically result in increased adverse medical outcomes associated with these medications, 50 not better outcomes as suggested by our findings.

We tried to minimize the effects of confounding in several different ways. First, we used an analysis with inverse probability weighting to minimize the effects of confounding by indication, 31 resulting in non-substantial between-group differences in clinical characteristics (all SMD<0.1) in both the IPW primary analysis and the Cox regression analysis in the matched analytic sample.

Second, we performed multiple sensitivity analyses, which showed similar results. Finally, although some amount of unmeasured confounding may remain, our analyses adjusted for numerous potential confounders. Other limitations include missing data for some baseline characteristic variables (i.e., 11.5%), which might be explained by the overwhelming of all hospital units during the COVID-19 peak incidence, and different results might have been observed during a lower COVID-19 incidence period. However, imputation of missing data did not alter the significance of our results (data available on request). Second, inflation of type I error might have occurred in exploratory analyses due to multiple testing. Third, data on several FIASMA medications were not available because no patients hospitalized for severe COVID-19 in AP-HP hospitals received them at study baseline during the first epidemic wave. Fourth, this study cannot establish a causal relationship between FIASMA medication use and reduced risk of intubation or death. Fifth, data to approximate the time to onset or duration of the potential effect of FIASMA medications and data on medications taken by patients prior to their hospital admission were not available. Although this may constitute a bias (i.e. considering patients taking a FIASMA medication just before hospital admission as not taking it instead of excluding them from the analyses), the direction of this bias is likely to be towards the null hypothesis, as it may

This article is protected by copyright. All rights reserved have led to underestimate the association between FIASMAs and reduced risk of intubation or mortality by including individuals taking FIASMAs just before hospital admission in the control group. Sixth, data cutoff is nearly a year ago and represents only the first few months of the COVID-19 pandemic. Furthermore, the relatively limited sample size reduced our ability to examine with adequate statistical power each individual FIASMA medication. Future studies would benefit in replicating our analyses while including a greater number of patients hospitalized for severe COVID-19 at a more recent time of the pandemic when care has substantially progressed as compared with its beginning. Finally, despite the multicenter design, our results may not be generalizable to outpatients or other regions.

In conclusion, in this multicenter observational retrospective study, FIASMA medication use was significantly and substantially associated with reduced risk of intubation or death among adult patients hospitalized for severe COVID-19. These findings show the potential importance of the ASM/ceramide system framework in COVID-19 treatment. They also support the continuation of 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

A stochastic agent-based model of the SARS-CoV-2 epidemic in France

Facing the COVID-19 epidemic in NYC: a stochastic agent-based model of various intervention strategies. medRxiv

Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review

Impact of the timing and adherence to face mask use on the course of the COVID-19 epidemic in France

Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells

Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications

Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs

Identification of novel functional inhibitors of acid sphingomyelinase

Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model

Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Accepted Article This article is protected by copyright. All rights reserved

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Association between Hydroxyzine Use and Reduced Mortality in Patients Hospitalized for Coronavirus Disease 2019: Results from a multicenter observational study. medRxiv

Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19

Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19. Cardiovasc

Observational study of haloperidol in hospitalized patients with COVID-19

Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19

Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study

Statement on the management at home or in a care facility of suspected or confirmed Covid-19 patients

Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Factors associated with COVID-19-related death using OpenSAFELY

Natural language processing for rapid response to emergent diseases: Case study of calcium channel blockers and hypertension in the COVID-19 pandemic

Accepted Article This article is protected by copyright. All rights reserved 26. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index 2021

& written on behalf of AME Big-Data Clinical Trial Collaborative Group Balance diagnostics after propensity score matching

Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research

Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research

Grambsch Modeling Survival Data: Extending the Cox Model

Marginal Structural Models and Causal Inference in Epidemiology

Nonparametric standard errors and confidence intervals

A Review of Its Mechanism of Action and Its Role in COVID-19

Inhibition of the replication of SARS-CoV-2 in human cells by the FDAapproved drug chlorpromazine

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells

High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication

Sigma-1 receptor antagonists haloperidol and chlorpromazine modulate the effect of glutoxim on NA+ transport in frog skin

Repurposing sigma-1 receptor ligands for Covid-19 therapy?

Comparative host-coronavirus protein interaction networks reveal panviral disease mechanisms

Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and metaanalysis

How COVID-19 induces cytokine storm with high mortality

The pathogenesis and treatment of theCytokine Storm'in COVID-19

Different influence of antipsychotics on the balance between pro-and anti-inflammatory cytokines depends on glia activation: an in vitro study

Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice

Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice

Association of antidepressant use with adverse health outcomes: a systematic umbrella review

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved a Defined as having a body-mass index higher than 30 kg/m 2 or an International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnosis code for obesity (E66.0, E66.1, E66.2, E66.8, E66.9). b Current smoking status was self-reported. c Any medication prescribed as part of a clinical trial or according to compassionate use (e.g., hydroxychloroquine, azithromycin, remdesivir, tocilizumab, sarilumab or dexamethasone). d Assessed using ICD-10 diagnosis codes for certain infectious and parasitic diseases (A00-B99). e Assessed using ICD-10 diagnosis codes for neoplasms (C00-D49) and diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89).f Assessed using ICD-10 diagnosis codes for mental, behavioural and neurodevelopmental disorders (F01-F99).g Assessed using ICD-10 diagnosis codes for diseases of the nervous system (G00-G99).h Assessed using ICD-10 diagnosis codes for diseases of the circulatory system (I00-I99).i Assessed using ICD-10 diagnosis codes for diseases of the respiratory system (J00-J99).j Assessed using ICD-10 diagnosis codes for diseases of the digestive system (K00-K95).k Assessed using ICD-10 diagnosis codes for diseases of the skin and subcutaneous tissue (L00-L99).l Assessed using ICD-10 diagnosis codes for diseases of the musculoskeletal system and connective tissue (M00-M99). m Assessed using ICD-10 diagnosis codes for diseases of the genitourinary system (N00-N99).n Assessed using ICD-10 diagnosis codes for endocrine, nutritional and metabolic diseases (E00-E89).o Assessed using ICD-10 diagnosis codes for diseases of the eye and adnexa (H00-H59) and diseases of the ear and mastoid process (H60-H95).

Abbreviation: SMD, standardized mean difference.

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved j Adjusted for age, sex, hospital, obesity, current smoking status, medication prescribed as part of a clinical trial or according to compassionate use, mental disorders, and endocrine disorders.* Two-sided p-value is significant (p<0.05).Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not applicable.